Our goal is to understand how nutrient-responsive signaling pathways can be harnessed to promote health and longevity. Rapamycin, an inhibitor of the protein kinase mTOR, can improve both health and longevity in model organisms including mammals. Understanding and manipulating the mTOR signaling pathway through dietary, pharmaceutical or genetic interventions may provide insight into the treatment of age-related diseases, including diabetes, Alzheimer’s disease, cancer, and Hutchinson-Gilford Progeria Syndrome.
- Dietary Interventions in Aging and Age-Related Disease
- Biology of Aging and mTOR
- Rapamcyin and rapalogs
The Lamming lab is supported in part by the NIH National Institute on Aging and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Other recent sources of support include the American Federation For Aging Research, the Glenn Foundation for Medical Research, the Progeria Research Foundation, and the Wisconsin Partnership Program.
Postdoctoral, Ph.D. students, M.D. students and undergraduates interested in pursuing research in the Lamming lab should contact Dr. Lamming directly at firstname.lastname@example.org.
May the #rapamycin be with you! Pleased to be able to announce our new review on "Targeting the biology of aging with #mTOR inhibitors" with @MannickJoan now available at @NatureAging. Free-to-read link now available at https://t.co/8cdajcZjCF pic.twitter.com/mMIxCWAx0Y— Lamming Lab (@LammingLab) May 4, 2023